Fibrin presence within aortic valves in patients with aortic stenosis: Association with in vivo thrombin generation and fibrin clot properties

Summary

A role of coagulation in the pathogenesis of aortic stenosis (AS) is unknown. The aim of this study was to investigate the fibrin (Fn) presence and its determinants in calcified stenotic aortic valve leaflets. Twenty-one patients with dominant AS and 17 well-matched patients with dominant aortic insufficiency (AI) undergoing aortic valve replacement were studied. Immunofluorescence analysis was performed on decalcified leaflets using antibodies against human Fn and tissue factor (TF). Fn-positive (41.4%) and TF-positive (25.3%) areas were increased in AS valves compared with AI valves (7.9% and 5.9%, respectively, both p<0.001). Patients with AS had elevated plasma D-dimer (236.4 ± 28 ng/ml, p=0.002) and prothrombin fragment 1+2 (F1.2) (261.7 ± 27.1 pM, p=0.005) compared to AI subjects (142.8 ± 10 ng/ml and 131.2 ± 1.3 pM, respectively). In AS patients Fn-positive areas correlated with TF-positive areas (r=0.68, p=0.0005), D-dimer (r=0.45, p=0.018), F1.2 (r=0.64, p=0.002), the time required for plasma fibrin clot formation (r=0.44, p=0.015) and maximum absorbance of fibrin clots (r=-0.38, p<0.0001), but not with clot permeability or lysis time. Thickness of Fn layer within AS valves was associated with maximum transvalvular gradient (r =0.41, p=0.048). Patients with maximal gradient above 75 mmHg (n=11) showed significant associations between Fn-positive area and both maximal (r =0.63) and mean (r =0.67) transvalvular gradients. Large fibrin amounts, mostly co-localised with TF, are present within the valve leaflets of patients with advanced AS. In vivothrombin generation and fibrin clot formation are associated with the extent of Fn presence within leaflets, which might contribute to the AS progression.

Keywords

Aortic stenosis - fibrin - clot structure - transvalvular gradient

• References

• 1 Pate GE. Association between aortic stenosis and hypertension. J Heart Valve Dis 2002; 11: 612-614.
• 2 Ngo MV, Gottdiener JS, Fletcher RD. et al. Smoking and obesity are associated with progression of aortic stenosis. Am J Geriatr Cardiol 2001; 10: 86-90.
• 3 Mohty D, Pibarot P, Després JP. et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008; 28: 187-193.
• 4 Novaro GM, Pearce GL, Sprecher DL. et al. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting. J Heart Valve Dis 2001; 10: 19-24.
• 5 Mohler ER III. Are atherosclerotic processes involved in aortic-valve calcification?. Lancet 2000; 356: 524-525.
• 6 Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009; 135: 4-13.
• 7 Otto CM, Kusist J, Reichenbach DD. et al. Characterization of the early lesion of “degenerative” valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994; 90: 844-853.
• 8 Ortlepp JR, Pilich M, Schmitz F. et al. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J Heart Valve Dis 2006; 15: 502-508.
• 9 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
• 10 Bini A, Fenoglio JJ, Mesa-Tejada R. et al. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9: 109-121.
• 11 Sato Y, Hatakeyama K, Yamashita A. et al. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart 2005; 91: 526-530.
• 12 Speiser W, Speiser P, Minar E. et al. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors. Thromb Res 1990; 59: 77-88.
• 13 Petkow DP, Hlawaty M, Undas A. et al. Effect of aortic valve stenosis on haemostasis is independent from vascular atherosclerotic burden. Atherosclerosis 2009; 204: 103-108.
• 14 Natorska J, Marek G, Hlawaty M. et al. Evidence for tissue factor expression in aortic valves in patients with aortic stenosis. Pol Arch Med Wew 2009; 119: 636-642.
• 15 Bini A, Fenoglio JJ, Sobel J. et al. Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood 1987; 69: 1038-1045.
• 16 Teirstein P, Yeager M, Yock PG. et al. Doppler echocardiographic measurement of aortic valve area in aortic stenosis: a noninvasive application of the Gorlin formula. J Am Coll Cardiol 1986; 8: 1059-1065.
• 17 Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: versalite software for automated biological image analysis. BioTechniques 2007; 42: 71-75.
• 18 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
• 19 Dong Z, Peng-Yuan Y, Bin Z. et al. Fibrin D-dimer fragments enhance inflammatory responses in macrophages: role in advancing atherosclerosis. Clin Experim Pharmacol Physiol 2007; 34: 185-190.
• 20 Marechaux S, Corseaux D, Vincentelli A. et al. Identification of tissue factor in experimental aortic valve sclerosis. Cardiovasc Path 2009; 18: 67-76.
• 21 Breyne J, Juthier F, Croseaux D. et al. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010 prepub online doi:10.1016/j.atherosclerosis.2010.07.047.
• 22 Mauriello A, Sangiorgi G, Palmieri G. et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation 2000; 101: 744-750.
• 23 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142.
• 24 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007; 196: 551-558.
• 25 Undas A, Kaczmarek P, Sladek K. et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease: beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176-1182.
• 26 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
• 27 Blombäck B, Carlsson K, Hessel B. et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
• 28 Goldsmith IRA, Blann AD, Patel RL. et al. Plasma fibrinogen, soluble P-selectin, and von Willebrand factor in aortic valve disease: evidence for abnormal haemorheology, platelet activation, and endothelial dysfunction. Heart 2000; 83: 577-578.
• 29 Naito N, Stirk CM, Smith EB. et al. Smooth muscle cell outgrowth stimulated by fibrin degradation products: the potential role of fibrin fragment E in restenosis and atherogenesis. Thromb Res 2000; 98: 165-174.
• 30 Pearson M, Lipowsky HH. Effect of fibrinogen on leukocyte migration and adhesion in postcapillary venules. Microcirculation 2004; 11: 295-306.